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In this issue of the Journal, a consensus statcment, developed 
by the American Heart Association (AHA) and endorsed by 
the American College of Cardiology Board of Trustees, ap- 
pears simultaneously with its publication in Circulation. The 
statement was developed by a consensus panel chaired bv 
Sidney C. Smith, Jr., MD, President of the AHA and included 
a group of experts in the field, most of whom arc fellows of the 
American College of Cardiology. The statement briefly out- 
lines the importance of risk reduction in the management of 
patients with established coronary artery disease, as well as 
those who have other manifestations of atherosclcrotic vascu- 
lar disease. Both the AHA and the College have for many 
years advocated and promoted the reduction of risk factors to 
decrease the likelihood that pcople free of atherosclerolic 
disease will develop it (primary.' prevention) and to slow or 
reverse the progression of the disease in those who have it 
(secondary prevention). 
Risk reduction in those with disease has always been 
important. Smoking cessation is, in my view, the single most 
important risk factor to control but remains difficult o achieve 
in some patients. Beta-blocker therapy after acute myocardial 
infarction has also bcen demonstrated to be effective in 
reducing long-term mortality, although this therapy has not 
been critically evaluated in a poplation of patients who have 
undergone infarct-related vessel reperfusion with thrombolytic 
therapy, coronary angioplasty or bypass surgery. The 
angiotensin-converting enzyme inhibitors have been demon- 
strated to improve the outcome of patients with left ventricular 
dysfunction after acute myocardial infarction. Although the 
mechanisms by which this protective ffect is achieved are not 
certain, it appears to be due in part to the reduction of 
recurrent myocardial infarction. 
Of great interest to all of us has been the continuing debate 
about the importance of lipid-lowering therapy for both pri- 
mary and seconda U prevention. Despite over'helming evi- 
dence for the relationship between hypcrlipidemia nd the 
development of coronary artery atherosclerolic disease, until 
very recently, it had not been possible to demonstrate hat 
lipid-lowering therapy reduced all-cause mortality. About the 
time that more effective lipid-loitering strategies became avail- 
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able, with the introduction of the first HGM-CoA reductase 
inhibitor, a series of angiograpbically based studies began to 
demonstrate a marked reduction in the progression of coro- 
nary atherosclerotic lesions and statistically significant regres- 
sion of some lesions (12). Although the degree of observed 
regression was usually small, several of these trials demon- 
strated an unexpected marked reduction i  new clinical events, 
such as death, recurrent myocardial infarction and the need for 
coronary' artery' revascularization. U fortunately, none of these 
angiographic trials were large enough to evaluate the effect of 
these powerful lipid-lowering therapies on all-cause mortality. 
The recent publication of the Scandinavian Simvastatin 
Survival Study (4S) (3) has finally ended the debate about he 
efficacy of lipid-lowering therapy in patients with moderate or 
hyperlipidemia nd coronary artery disease. In addition to 
convincingly demonstrating that aggressive lipid-lowering ther- 
apy reduces both all-cause mortality and mortality from recur- 
rent acute myocardial infarction, this trial showed an impor- 
tant reduction in stroke not previously demonstrated with 
lipid-lowering therapy. 
Thc American Heart Association, under the capable lead- 
ership of Dr. Sidney C. Smith, Jr., is making a major effort to 
educate physicians, patients and the public about he benefits 
of secondary prevention. I strongly recommend that all of the 
members of the American College of Cardiology and all 
physicians who care for patients with coronary artery disease 
join in this important effort. It is critically important that our 
patients have appropriate lipid evaluation and that those with 
significant hyperlipidemia be considered for aggressive lipid- 
lowering therapy. In my experience, the majority of these 
patients will require drug therapy in addition to diet to achieve 
the degree of reduction in low density lipoprotein that is 
necessary to reduce death from myocardial infarction and 
stroke and to improve overall survival. 
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